We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East
Monthly Production Capacity: 1000kg
Packaging Information: 25kg/drum 1kg/bottle
Delivery Lead Time: 7 days after payment
Sample Provided: yes
Payment Terms: L/L
Product Information
Product name
Nilotinib
CAS No.
641571-10-0
Molecular Formula
C28H22F3N7O
Molecular Weight
529.523
Quality Standard
99% up by HPLC
Appearance
White to pale yellow powder
Usage
Function of Nilotinib
Nilotinib is improved from the molecular structure of imatinib, and has stronger selectivity for BCR-ABL kinase activity, and its inhibitory effect on tyrosine kinase is 30 times stronger than that of imatinib, which can inhibit Kinase activity of imatinib-resistant BCR-ABL mutants, while also inhibiting KIT and PDGFR kinase activities. For the treatment of chronic myeloid leukemia (CML), a life-threatening blood cancer that is refractory to or intolerable to imatinib mesylate. Based on a pivotal Phase II clinical study design evaluating the positive results of oral nilotinib in clinical trials against imatinib mesylate or in patients with Ph+ CML in the slow and accelerated phases of apparent toxicity: High efficacy, good tolerance, and manageable safety.
Twenty years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
